Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma
Yıl: 2022 Cilt: 47 Sayı: 2 Sayfa Aralığı: 596 - 602 Metin Dili: İngilizce DOI: 10.17826/cumj.1039267 İndeks Tarihi: 29-07-2022
Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma
Öz: Purpose: Some patients with cancer use herbal therapy as an adjunct while receiving conventional cancer treatments. Beta-glucans have direct cytotoxic effects on cancer cells as well as stimulatory effects on the immune system. In this study, a nutritional supplement containing 1,3-1,6 beta-glucan obtained from baker's yeast (Saccharomyces cerevisiae) was used by patients diagnosed with sarcoma, and this study aimed to retrospectively evaluate the effect of beta-glucan use on the incidence of neutropenic fever (NF) and survival rates.
Materials and Methods: Among the patients diagnosed with sarcoma between 2014 and 2017, 27 patients who used beta-glucan were included in the beta-glucan group, and 31 patients who did not use beta-glucan were included in the control group. The clinical records of patients were retrospectively analyzed.
Results: The number of patients who had NF and the mean length of hospital stay due to NF were higher in the beta-glucan group than those in the control group, but the results were not statistically significant. The overall survival rates at 5 years were 83.3% and 52.9% and event-free survival rates at 5 years were 48.1% and 71% in the beta-glucan and control groups, respectively.
Conclusion: The effect of prophylactic beta-glucan use on the incidence of NF and survival rates in pediatric patients with sarcoma should be evaluated more reliably in further prospective studies on a large patient group.
Anahtar Kelime: Pediatrik sarkom hastalarında profilaktik beta-glukan kullanımının nötropenik ateş sıklığı ve sağkalım üzerine etkisi
Öz: Amaç: Kanser hastalarının bir kısmı, geleneksel kanser tedavilerini alırken, tamamlayıcı bitkisel tedavi kullanma eğilimindedir. Beta-glukanların bağışıklık sistemini uyarıcı etkisi yanında, kanser hücreleri üzerine doğrudan sitotoksik etkileri de vardır. Bu çalışmada, ekmek mayasından (Saccharomyces cerevisiae) elde edilen, 1,3-1,6 beta-glukan içeren besin takviyesi, sarkom tanılı hastalar tarafından kullanılmış ve retrospektif olarak beta-glukan kullanımının nötropenik ateş (NA) sıklığı ve sağkalım üzerine etkisinin değerlendirilmesi amaçlanmıştır.
Gereç ve Yöntem: 2014-2017 yılları arasında sarkom tanısı alan, beta-glukan kullanmış 27 hasta ve kontrol grubu olarak beta-glukan kullanmamış 31 hasta alındı. Hastaların klinik kayıtları geriye dönük olarak incelendi.
Bulgular: Beta-glukan grubunda NA geçiren hasta sayısı ve NA nedeniyle hastanede ortalama yatış süresi kontrol grubuna göre daha yüksekti ancak sonuçlar istatistiksel olarak anlamlı değildi. Genel sağkalım ve olaysız sağkalım açısından bakıldığında, beta-glukan ve kontrol grubunda 5. yılda genel sağkalım %83,3 ve %52,9, 5. yılda olaysız sağkalım %48,1 ve %71 idi.
Sonuç: Daha geniş hasta grubu ile prospektif olarak dizayn edilecek çalışmalar ile profilaktik beta-glukan kullanımının nötropenik ateş sıklığı ve sağ kalım oranları üzerine etkisi daha sağlıklı olarak değerlendirilebilir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. McEachrane-Gross FP, Liebschutz JM, Berlowitz D. Use of selected complementary and alternative medicine (CAM) treatments in veterans with cancer or chronic pain: a cross-sectional survey BMC. Complement Altern Med. 2006;6:34.
- 2. Maheshwari G, Sowrirajan S, Joseph B. Extraction and isolation of beta-glucan from grain sources-a review. J. Food Sci. 2017;82:1535–45.
- 3. Batbayar S, Lee DH, Kim HW. Immunomodulation of fungal b-glucan in host defense signaling by dectin1. Biomol Ther. 2012;20:433–45.
- 4. Chen J, Zhang XD, Jiang Z. The application of fungal β-glucans for the treatment of colon cancer. Anticancer Agents Med Chem. 2013;13:725-30.
- 5. Lehrnbecher T, Phillips R, Alexander S, Ammann RA, Beauchemin M, Carlesse F et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427-38.
- 6. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52(4): 56- 93.
- 7. Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: Results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol. 2014;32:2440–8.
- 8. Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Kraib MD et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed highgrade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17:1396-1408.
- 9. Arndt CAS, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol. 2009;27:5182-8.
- 10. Ardura MI, Koh AY. Infectious complications in children with underlying malignancy. In Pizzo and Poplack’s Pediatric Oncology, 8th ed. (Eds Blaney SM, Helman LJ, Adamson PC). Philadelphia: Wolters Kluwer, 2021:955-1001.
- 11. McLean TW, Sencer SF. Complementary and integrative therapies in pediatric oncology. In Pizzo and Poplack’s Pediatric Oncology, 8th ed. (Eds Blaney SM, Helman LJ, Adamson PC). Philadelphia: Wolters Kluwer, 2021:1197-206.
- 12. Diorio C, Lam CG, Ladas EJ, Njuguna F, Afungchwi GM, Taromina K et al. Global use of traditional and complementary medicine in childhood cancer: a systematic review. J Glob Oncol. 2017;3:791–800.
- 13. Karlik JB, Ladas EJ, Ndao DH, Cheng B, Bao YY, Kelly KM. Associations between healthy lifestyle behaviors and complementary and alternative medicine use: integrated wellness. J Natl Cancer Inst Monogr. 2014;2014:323–9.
- 14. Hardy ML. Dietary supplement use in cancer care: help or harm. Hematol Oncol Clin N Am. 2008;22:581-617.
- 15. Sonck E, Stuyven E, Goddeeris B, Cox E. The effect of beta-glucans on porcine leukocytes. Vet Immunol Immunopathol. 2010;135:199-207.
- 16. Xiao Z, Trincado CA, Murtaugh MP. Beta-glucan enhancement of T cell IFN gamma response in swine. Vet Immunol Immunopathol. 2004;102:315-20.
- 17. Steimbach L, Borgmann AV, Gomar GG, Hoffmann LV, Rutckeviski R, Pereira de Andrade D et al. Fungal beta-glucans as adjuvants for treating cancer patients - A systematic review of clinical trials. Clin Nutr. 2021;40:3104-13.
- 18. De Graaff P, Govers C, Wichers HJ, Debets R. Consumption of b -glucans to spice up T cell treatment of tumors : a review. Expert Opin Biol Ther. 2018;18:1023-40.
- 19. Karaca H, Bozkurt O, Ozaslan E, Debets R. Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy. Asian Pac J Cancer Prev. 2014;15:3641-4.
- 20. Demir G, Klein HO, Mandel-Molinas N, Tuzuner N. Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int Immunopharmacol. 2007;7:113-6.
- 21. Ostadrahimi A, Ziaei JE, Esfahani A, Jafarabadi MA, Movassaghpourakbari A, Farrin N. Effect of beta glucan on white blood cell counts and serum levels of IL-4 and IL-12 in women with breast cancer undergoing chemotherapy: a randomized doubleblind placebo-controlled clinical trial. Asian Pac J Cancer Pre. 2014;15:5733-9.
- 22. Aleem E. β-Glucans and their applications in cancer therapy: focus on human studies. Anticancer Agents Med Chem. 2013;13:709-19.
- 23. Engel-Riedel W, Lowe J, Mattson P, Trout JR, Huhn RD, Gargano M et al. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced nonsmall cell lung cancer. J Immunother Cancer. 2018;6:1-14.
- 24. Garami M, Schuler D, Babosa M, Borgulya G, Hauser P, Müller J et al. Fermented wheat germ extract reduces chemotherapy induced febrile neutropenia in pediatric cancer patients. J Pediatr Hematol Oncol. 2004;26:631–5.
- 25. Castelán-Martínez OD, Palomo-Colli MA, BarriosLópez VE, Silva-Jivaja KM, Juárez-Villegas LE, Castañeda-Hernández G et al. Efficacy and safety of oral magnesium supplementation in reducing febrile neutropenia episodes in children with solid tumors treated with cisplatin-based chemotherapy: randomized clinical trial. Cancer Chemother Pharmacol. 2020;86:673-9.
- 26. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633-8.
- 27. Taçyıldız N, Unal E, Dinçaslan H, Çakmak HM, Köse K, Tanyıldız G et al. Muramyl tripeptide plus chemotherapy reduces metastasis in non-metastatic osteosarcoma: a single-center experience. Asian Pac J Cancer Prev. 2020;21:715-20.
- 28. Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results. J Clin Oncol. 2008;26:3103-4.
- 29. Bielack SS, Marina N, Ferrari S, Helman LJ, Smeland S, Whelan JS et al. Osteosarcoma: the same old drugs or more? J Clin Oncol. 2008;26:3102-3.
| APA | Ozkan A, Küpeli S, ÇIL M, Sezgin G, BAYRAM İ (2022). Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma. , 596 - 602. 10.17826/cumj.1039267 |
| Chicago | Ozkan Ayse,Küpeli Serhan,ÇIL METIN,Sezgin Gülay,BAYRAM İBRAHİM Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma. (2022): 596 - 602. 10.17826/cumj.1039267 |
| MLA | Ozkan Ayse,Küpeli Serhan,ÇIL METIN,Sezgin Gülay,BAYRAM İBRAHİM Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma. , 2022, ss.596 - 602. 10.17826/cumj.1039267 |
| AMA | Ozkan A,Küpeli S,ÇIL M,Sezgin G,BAYRAM İ Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma. . 2022; 596 - 602. 10.17826/cumj.1039267 |
| Vancouver | Ozkan A,Küpeli S,ÇIL M,Sezgin G,BAYRAM İ Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma. . 2022; 596 - 602. 10.17826/cumj.1039267 |
| IEEE | Ozkan A,Küpeli S,ÇIL M,Sezgin G,BAYRAM İ "Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma." , ss.596 - 602, 2022. 10.17826/cumj.1039267 |
| ISNAD | Ozkan, Ayse vd. "Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma". (2022), 596-602. https://doi.org/10.17826/cumj.1039267 |
| APA | Ozkan A, Küpeli S, ÇIL M, Sezgin G, BAYRAM İ (2022). Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma. Cukurova Medical Journal, 47(2), 596 - 602. 10.17826/cumj.1039267 |
| Chicago | Ozkan Ayse,Küpeli Serhan,ÇIL METIN,Sezgin Gülay,BAYRAM İBRAHİM Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma. Cukurova Medical Journal 47, no.2 (2022): 596 - 602. 10.17826/cumj.1039267 |
| MLA | Ozkan Ayse,Küpeli Serhan,ÇIL METIN,Sezgin Gülay,BAYRAM İBRAHİM Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma. Cukurova Medical Journal, vol.47, no.2, 2022, ss.596 - 602. 10.17826/cumj.1039267 |
| AMA | Ozkan A,Küpeli S,ÇIL M,Sezgin G,BAYRAM İ Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma. Cukurova Medical Journal. 2022; 47(2): 596 - 602. 10.17826/cumj.1039267 |
| Vancouver | Ozkan A,Küpeli S,ÇIL M,Sezgin G,BAYRAM İ Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma. Cukurova Medical Journal. 2022; 47(2): 596 - 602. 10.17826/cumj.1039267 |
| IEEE | Ozkan A,Küpeli S,ÇIL M,Sezgin G,BAYRAM İ "Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma." Cukurova Medical Journal, 47, ss.596 - 602, 2022. 10.17826/cumj.1039267 |
| ISNAD | Ozkan, Ayse vd. "Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma". Cukurova Medical Journal 47/2 (2022), 596-602. https://doi.org/10.17826/cumj.1039267 |
